Osteoporosis Treatment and Outcomes in Patients Undergoing Adult Spinal Deformity Surgery
Thomas Shen,Hania Shahzad,Frank Sierra,Joseph B Wick,Dagoberto Pina,Benjamin W Van,Wyatt D Vander Voort,Shana Kong,Yashar Javidan,Rolando F Roberto,Eric O Klineberg,Hai V Le
DOI: https://doi.org/10.1016/j.wneu.2024.08.053
2024-08-16
Abstract:Adult spinal deformity (ASD) treatment for patients with osteoporosis presents a unique challenge for spine surgeons, particularly with ensuring adequate fixation and correction during surgery and due to the risk of treatment failure and complications thereafter. Osteoporosis is characterized by low bone mineral density (BMD) which may increase the risk for fractures. Approximately 12.6% of all adults over 50 years old in the United States are affected by osteoporosis, and the prevalence is predicted to increase with the aging population.1 ASD patients experience substantially higher rates of osteoporosis compared to the general population.2,3 One study discovered an osteoporosis prevalence of nearly 33% in a cohort of ASD patients undergoing long spinal fusion at two academic medical centers, with slightly over one- third of those patients receiving osteoporosis pharmacotherapy prior to surgery.3 Similarly, patients with osteoporosis experience ASD at higher rates than the general population, with one study finding that 9.5% of patients with osteoporosis suffer from ASD symptoms.3 Gupta et al. discovered that obtaining a DEXA scan of the forearm in addition to the hip allowed physicians to detect an additional 17% incidence of osteoporosis in ASD patients, suggesting that osteoporosis may be missed when there is only one DEXA scan available.4In addition to being potentially underdiagnosed and undertreated, ASD patients with osteoporosis experience higher rates of post-surgical complications. Pseudarthrosis, or nonunion after spinal fusion, is a painful and potentially debilitating complication following ASD surgery that ultimately requires additional surgical correction. Proximal junctional kyphosis (PJK), which is defined as proximal junctional sagittal Cobb angle ≥ 10° and at least 10° greater than the preoperative measurement, is another complication of ASD surgery.5 Though this condition may be clinically silent and manifest purely as a radiographic diagnosis, it is often a precursor to proximal junctional failure (PJF), a more severe form of PJK that ultimately increases the risk for intractable pain, neurological deficit, and revision surgery.6 ASD patients with osteoporosis experience significantly higher rates of pseudarthrosis, PJK, PJF, and postoperative fractures, as well as other forms of instrumentation failure requiring additional surgical treatment.7-11 This ultimately increases the pain, emotional burden, and morbidity experienced by patients. There is currently conflicting data regarding the impact of perioperative osteoporosis pharmacotherapy on outcomes in ASD patients. Bisphosphonates are considered first-line treatment for osteoporosis, though alternatives such as teriparatide, denosumab, and calcitonin may be used as well.12 Multiple studies have found that preoperative bisphosphonate treatment did not affect lumbar fusion nonunion rates.13,14 In contrast, a meta-analysis of randomized control trials found that postoperative bisphosphonates had no effect on lumbar fusion rates but did significantly reduce the risk of vertebral compression fracture (VCF) and pedicle screw loosening at 12-month follow-up.15 Prophylactic teriparatide treatment has been associated with improved BMD and lower incidence of PJK type-2 in osteoporosis patients who underwent ASD surgery.16 Evidence for perioperative treatment of teriparatide as a preventative step to increase fusion rates and reduce PJK and PJF is strongest.17 However, the percentage of ASD patients who are actually being treated perioperatively with these medications requires further evaluation, and a comparison of outcomes with osteoporosis and non-osteoporosis counterparts has yet to be explored. The purpose of this study was to evaluate the prevalence and treatment of osteoporosis among patients undergoing long spinal fusion for ASD, as well as compare the impact of osteoporosis treatment on surgical and radiographic outcomes following fusion surgery. Additionally, we sought to examine the differences in radiographic outcomes of osteoporotic patients receiving various pharmacologic regimens such as monotherapy vs combination therapy.